FDA Determines Semaglutide Shortage is Resolved
The FDA has determined that the shortage of semaglutide, a GLP-1 receptor agonist, has been resolved. The agency confirmed that manufacturers can meet current and projected national demand, though some localized supply disruptions may persist. As a result, the FDA reminds compounders of legal restrictions on producing copies of FDA-approved drugs, emphasizing that compounded versions must meet specific conditions under federal law.